FDA Approves Medication to Prevent Hearing Loss During Childhood Cancer Treatment | Fennec Pedmark

Fennec Pharmaceuticals Inc, a specialty pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for the company’s unique formulation of sodium thiosulfate (STS) called Pedmark for the prevention of platinum-induced ototoxicity in pediatric patients one month to 18 years of age with localized, non-metastatic, solid tumors. Pedmark had previously received both Breakthrough Therapy and Fast Track Designation by the FDA in March 2018.

Read more: https://www.hearingtracker.com/news/fda-approves-fennec-hearing-loss-treatment-for-pediatric-cancer-patients-treated-with-cisplatin

__________________________________________________________________________________________
Matthew Allsop is the Video Content Manager at Hearingtracker.com. He practices from his London-based practice, Harley Street Hearing. You can get in touch on matthew@hearingtracker.com regarding new content ideas or to become a patient.

#hearing #hearingloss #hearingaids

Видео FDA Approves Medication to Prevent Hearing Loss During Childhood Cancer Treatment | Fennec Pedmark канала HearingTracker